Related Experiment Video
Updated: Sep 12, 2025

Author Spotlight: Developing a Rat Model for Weight-Bearing Intervention to Investigate Osteonecrosis of the Femoral Head
Published on: September 27, 2024
Glucocorticoids induce femoral head necrosis in rats through the HIF-1α/VEGF signaling pathway
HaoXu Tang1,2, Lingli Yuan3, ZhiYuan Xu4
1Department of the Second Affiliated Hospital of Bengbu Medical University, Anhui, China.
Abstract:
Glucocorticoid-induced osteoblast dysfunction is the primary cause of steroid-induced osteonecrosis of the femoral head (SONFH). However, the specific underlying biological mechanisms of glucocorticoids' effect on osteoblasts remain undetermined. Recently, the role of hypoxia-inducible factor 1-alpha (HIF-1α)/vascular endothelial growth factor (VEGF) signaling pathway in modulating bone formation has been studied. This study aimed to investigate the association and mechanism of the HIF-1α/VEGF signaling pathway in glucocorticoid-induced osteogenesis suppression in MC3T3-E1 cells. This study performed CCK8 and live/dead staining assays by stimulating MC3T3-E1 cells with varying dexamethasone (DEX) doses to elucidate its influence on cell proliferation and activity. Furthermore, Western blotting was carried out to investigate the expression of HIF-1α, runt-related transcription factor 2 (RUNX2), VEGF, osteopontin (OPN), and alkaline phosphatase (ALP) proteins to identify the optimal DEX concentration for simulating steroid-induced osteonecrosis cell models. Moreover, the osteogenic differentiation of cells was assessed by transfecting them with control or HIF-1α overexpression lentiviral vectors. Similarly, in vivo, hematoxylin and eosin staining, immunohistochemical staining, and micro-computed tomography were performed to validate in vitro results in the SONFH rat model. In vitro analyses revealed that a 10- 6 M concentration of DEX significantly suppressed cell viability and osteogenesis by decreasing HIF-1α and VEGF levels. Furthermore, HIF-1α upregulation increased osteogenic activity and VEGF expression in MC3T3-E1 cells. However, the HIF-1α antagonist 3-(5'-hydroxymethyl-2'-furyl) -1-benzylindazole (YC-1) indicated opposite effects in DEX-treated MC3T3-E1 cells. Moreover, SONFH femoral heads had reduced bone density, bone tissue content, and femoral head integrity, as well as increased bone cell lacunae, while decreased HIF-1α, OPN, VEGF, and ALP levels in bone tissue compared to normal rats. This study indicated that DEX suppresses osteoblast differentiation via the HIF-1α/VEGF pathway, thus promoting SONFH.
Insights
Glucocorticoids suppress osteoblast function and bone formation by inhibiting the hypoxia-inducible factor 1-alpha (HIF-1α)/vascular endothelial growth factor (VEGF) pathway, leading to steroid-induced osteonecrosis of the femoral head (SONFH).
Area of Science:
- Biomedical Sciences
- Cell Biology
- Bone Biology
Background:
- Glucocorticoid-induced osteoblast dysfunction is the primary cause of steroid-induced osteonecrosis of the femoral head (SONFH).
- The precise mechanisms by which glucocorticoids impair osteoblast function remain unclear.
- The hypoxia-inducible factor 1-alpha (HIF-1α)/vascular endothelial growth factor (VEGF) pathway is implicated in bone formation regulation.
Purpose of the Study:
- To investigate the role and mechanism of the HIF-1α/VEGF signaling pathway in glucocorticoid-induced osteogenesis suppression.
- To elucidate the effects of dexamethasone (DEX) on osteoblast function and SONFH development.
Main Methods:
- In vitro: MC3T3-E1 cells treated with varying dexamethasone (DEX) concentrations; CCK8 and live/dead assays for cell viability; Western blotting for protein expression (HIF-1α, RUNX2, VEGF, OPN, ALP); lentiviral vectors for HIF-1α overexpression; HIF-1α antagonist (YC-1) treatment.
- In vivo: SONFH rat model; hematoxylin and eosin staining, immunohistochemical staining, and micro-computed tomography for bone assessment.
Main Results:
- Dexamethasone (10⁻⁶ M) significantly suppressed MC3T3-E1 cell viability and osteogenesis, decreasing HIF-1α and VEGF levels.
- HIF-1α upregulation enhanced osteogenic activity and VEGF expression in DEX-treated cells, while the HIF-1α antagonist YC-1 reversed these effects.
- In the SONFH rat model, reduced bone density, tissue content, and femoral head integrity were observed, alongside decreased HIF-1α, OPN, VEGF, and ALP levels.
Conclusions:
- Dexamethasone suppresses osteoblast differentiation and promotes SONFH by inhibiting the HIF-1α/VEGF signaling pathway.
- Targeting the HIF-1α/VEGF pathway may offer a therapeutic strategy for preventing or treating glucocorticoid-induced osteonecrosis.
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Regulation of Angiogenesis and Blood Supply
TGF - β Signaling Pathway

